MAPT and Alzheimer disease: In AD animal models, DPP-4i inhibitors treatment (saxagliptin, vildagliptin, sitagliptin) decreases tau phosphorylation, amyloid load and inflammatory markers but also reverses the cognitive deficits with memory improvement [97,98].